On 15 MAY DARA Biosciences Inc (NASDAQ:DARA) announced its support for Neuropathy Awareness Week which is being observed during the week and sponsored in the U.S. by The Neuropathy Association. DARA Biosciences Inc (NASDAQ:DARA) weekly performance is -5.98%. On last trading day company shares ended up $1.10. Analysts mean target price for the company is $2.00. DARA Biosciences Inc (NASDAQ:DARA) distance from 50-day simple moving average (SMA50) is -49.51%.
On 23 MAY CorMedix Inc. (NYSEMKT: CRMD) announces the receipt of a notice indicating that CorMedix did not meet certain of the NYSE MKT LLC’s continued listing standards as set forth in the NYSE MKT Company Guide (“Company Guide”). CorMedix Inc. (NYSEMKT: CRMD) shares advanced 6.86% in last trading session and ended the day on $1.40. CRMD return on assets is -822.20%. CorMedix Inc. (NYSEMKT: CRMD) quarterly performance is -37.78%.
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced that Nadav Kidron, the Company’s Chief Executive Officer, will deliver a corporate presentation at the Jefferies Global Healthcare Conference taking place from June 2-5, 2014, in New York City. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares moved down -8.95% in last trading session and was closed at $7.02, while trading in range of $6.95 – $7.60. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) year to date (YTD) performance is -54.50%.
On 2 MAY OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) declared a loss of 59 cents per share in the first quarter of 2014, lesser than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 46 cents per share. First quarter 2014 revenues came in $11.7 million, higher 131.1% from the year-ago quarter. Revenues overtook the Zacks Consensus Estimate of $9 million. Revenues moved up because of patient enrolment and therapy in the AFFINITY study. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) ended the last trading day at $3.86. Company weekly volatility is calculated as 5.63% and price to cash ratio as 1.52. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) showed a negative weekly performance of -0.77%.
On 13 MAY Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced financial results for the first quarter ended March 31, 2014, Net loss for first quarter 2014 was $5.2 million compared with $2.3 million for first quarter 2013. Research and development expenses were $3.7 million for first quarter 2014 compared with $1.0 million for first quarter 2013. General and administrative expenses were $1.6 million for first quarter 2014 compared with $0.7 million for first quarter 2013. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) weekly performance is 8.94%. On last trading day company shares ended up $6.09. Analysts mean target price for the company is $15.25. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) distance from 50-day simple moving average (SMA50) is -14.85%.